Drastic antitumor response following administration of afatinib immediately after atezolizumab in a patient with epidermal growth factor receptor tyrosine kinase inhibitor‐resistant lung cancer

Drastic antitumor response following administration of afatinib immediately after atezolizumab in a patient with epidermal growth factor receptor tyrosine kinase inhibitor‐resistant lung cancer

Bibliographic Details
Main Authors: Toshiyuki Sumi, Hisashi Nakata, Hirofumi Chiba
Format: Article
Language:English
Published: Wiley 2021-07-01
Series:Thoracic Cancer
Subjects:
afatinib
atezolizumab
rechallenge
Online Access:https://doi.org/10.1111/1759-7714.14047
id doaj-350bb832def24d9a858d4e43efffc445
record_format Article
spelling doaj-350bb832def24d9a858d4e43efffc4452021-07-06T06:23:18ZengWileyThoracic Cancer1759-77061759-77142021-07-0112132050205210.1111/1759-7714.14047Drastic antitumor response following administration of afatinib immediately after atezolizumab in a patient with epidermal growth factor receptor tyrosine kinase inhibitor‐resistant lung cancerToshiyuki Sumi0Hisashi Nakata1Hirofumi Chiba2Department of Pulmonary Medicine Hakodate Goryoukaku Hospital Hakodate JapanDepartment of Pulmonary Medicine Hakodate Goryoukaku Hospital Hakodate JapanDepartment of Respiratory Medicine and Allergology Sapporo Medical University School of Medicine Sapporo Japanhttps://doi.org/10.1111/1759-7714.14047afatinibatezolizumabrechallenge
collection DOAJ
language English
format Article
sources DOAJ
author Toshiyuki Sumi
Hisashi Nakata
Hirofumi Chiba
spellingShingle Toshiyuki Sumi
Hisashi Nakata
Hirofumi Chiba
Drastic antitumor response following administration of afatinib immediately after atezolizumab in a patient with epidermal growth factor receptor tyrosine kinase inhibitor‐resistant lung cancer
Thoracic Cancer
afatinib
atezolizumab
rechallenge
author_facet Toshiyuki Sumi
Hisashi Nakata
Hirofumi Chiba
author_sort Toshiyuki Sumi
title Drastic antitumor response following administration of afatinib immediately after atezolizumab in a patient with epidermal growth factor receptor tyrosine kinase inhibitor‐resistant lung cancer
title_short Drastic antitumor response following administration of afatinib immediately after atezolizumab in a patient with epidermal growth factor receptor tyrosine kinase inhibitor‐resistant lung cancer
title_full Drastic antitumor response following administration of afatinib immediately after atezolizumab in a patient with epidermal growth factor receptor tyrosine kinase inhibitor‐resistant lung cancer
title_fullStr Drastic antitumor response following administration of afatinib immediately after atezolizumab in a patient with epidermal growth factor receptor tyrosine kinase inhibitor‐resistant lung cancer
title_full_unstemmed Drastic antitumor response following administration of afatinib immediately after atezolizumab in a patient with epidermal growth factor receptor tyrosine kinase inhibitor‐resistant lung cancer
title_sort drastic antitumor response following administration of afatinib immediately after atezolizumab in a patient with epidermal growth factor receptor tyrosine kinase inhibitor‐resistant lung cancer
publisher Wiley
series Thoracic Cancer
issn 1759-7706
1759-7714
publishDate 2021-07-01
topic afatinib
atezolizumab
rechallenge
url https://doi.org/10.1111/1759-7714.14047
work_keys_str_mv AT toshiyukisumi drasticantitumorresponsefollowingadministrationofafatinibimmediatelyafteratezolizumabinapatientwithepidermalgrowthfactorreceptortyrosinekinaseinhibitorresistantlungcancer
AT hisashinakata drasticantitumorresponsefollowingadministrationofafatinibimmediatelyafteratezolizumabinapatientwithepidermalgrowthfactorreceptortyrosinekinaseinhibitorresistantlungcancer
AT hirofumichiba drasticantitumorresponsefollowingadministrationofafatinibimmediatelyafteratezolizumabinapatientwithepidermalgrowthfactorreceptortyrosinekinaseinhibitorresistantlungcancer
_version_ 1721318056579301376

Similar Items